RGNX – REGENXBIO Inc.
REGENXBIO Inc.RGNX
$6.34Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $327,762,912.00
EPSttm : -5.6
REGENXBIO Inc.
$6.34
3.43%$0.21
RGNX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
15.27
Margin Of Safety %
Put/Call OI Ratio
0.47
EPS Next Q Diff
0.24
EPS Last/This Y
0.91
EPS This/Next Y
0.33
Price
6.33
Target Price
25.58
Analyst Recom
1.42
Performance Q
-35.96
Upside
-1,246.2%
Beta
1.05
Ticker: RGNX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | RGNX | 10.07 | 0.56 | 0.42 | 8843 |
| 2026-05-12 | RGNX | 10.25 | 0.58 | 3.12 | 9428 |
| 2026-05-13 | RGNX | 10.03 | 0.68 | 1.64 | 10414 |
| 2026-05-14 | RGNX | 6.24 | 0.76 | 1.26 | 11644 |
| 2026-05-15 | RGNX | 5.71 | 0.61 | 1.34 | 13525 |
| 2026-05-18 | RGNX | 5.64 | 0.39 | 1.47 | 7682 |
| 2026-05-19 | RGNX | 5.64 | 0.49 | 0.72 | 9098 |
| 2026-05-20 | RGNX | 5.95 | 0.49 | 1.25 | 9487 |
| 2026-05-21 | RGNX | 6.76 | 0.53 | 0.04 | 10227 |
| 2026-05-22 | RGNX | 6.35 | 0.46 | 1.00 | 11331 |
| 2026-05-26 | RGNX | 6.3 | 0.47 | 0.09 | 11442 |
| 2026-05-27 | RGNX | 6.69 | 0.46 | 0.05 | 11625 |
| 2026-05-28 | RGNX | 6.88 | 0.46 | 0.00 | 11625 |
| 2026-05-29 | RGNX | 7.03 | 0.46 | 0.06 | 11619 |
| 2026-06-02 | RGNX | 6.53 | 0.45 | 0.13 | 11853 |
| 2026-06-03 | RGNX | 6.69 | 0.45 | 0.25 | 11864 |
| 2026-06-04 | RGNX | 6.87 | 0.45 | 1.82 | 11866 |
| 2026-06-05 | RGNX | 6.07 | 0.45 | 1.14 | 11843 |
| 2026-06-08 | RGNX | 6.12 | 0.48 | 5.38 | 12099 |
| 2026-06-09 | RGNX | 6.33 | 0.47 | 2.15 | 12091 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | RGNX | 10.06 | -1278.3 | 221.6 | -2.00 |
| 2026-05-12 | RGNX | 10.26 | -1278.3 | 223.7 | -2.00 |
| 2026-05-13 | RGNX | 10.05 | -1278.3 | 221.5 | -2.00 |
| 2026-05-14 | RGNX | 6.24 | -1278.3 | 182.1 | -2.00 |
| 2026-05-15 | RGNX | 5.72 | -1278.3 | 176.7 | -2.00 |
| 2026-05-18 | RGNX | 5.65 | -1278.3 | - | -2.00 |
| 2026-05-19 | RGNX | 5.65 | -1278.3 | - | -2.00 |
| 2026-05-20 | RGNX | 5.95 | 104.6 | - | -2.08 |
| 2026-05-21 | RGNX | 6.76 | 104.6 | - | -2.08 |
| 2026-05-22 | RGNX | 6.36 | 125.0 | - | -2.85 |
| 2026-05-26 | RGNX | 6.31 | 125.0 | - | -2.85 |
| 2026-05-27 | RGNX | 6.69 | 125.0 | - | -2.85 |
| 2026-05-28 | RGNX | 6.88 | 125.0 | - | -2.85 |
| 2026-05-29 | RGNX | 7.03 | 125.0 | - | -2.85 |
| 2026-06-01 | RGNX | 7.14 | 125.0 | - | -2.85 |
| 2026-06-02 | RGNX | 6.55 | 125.0 | - | -2.85 |
| 2026-06-03 | RGNX | 6.68 | 125.0 | - | -2.85 |
| 2026-06-04 | RGNX | 6.88 | 125.0 | - | -2.85 |
| 2026-06-05 | RGNX | 6.07 | 125.0 | - | -2.85 |
| 2026-06-08 | RGNX | 6.13 | 125.0 | - | -2.85 |
| 2026-06-09 | RGNX | 6.33 | 125.0 | - | -2.85 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | RGNX | -0.09 | -0.49 | 15.08 |
| 2026-05-12 | RGNX | -0.09 | -0.49 | 14.53 |
| 2026-05-13 | RGNX | -0.09 | -0.49 | 14.53 |
| 2026-05-14 | RGNX | -0.37 | -0.49 | 14.53 |
| 2026-05-15 | RGNX | -0.37 | -0.49 | 14.53 |
| 2026-05-18 | RGNX | -0.37 | -0.49 | 14.15 |
| 2026-05-19 | RGNX | -0.46 | -0.49 | 14.28 |
| 2026-05-20 | RGNX | -0.42 | -0.49 | 14.28 |
| 2026-05-21 | RGNX | -0.42 | -0.49 | 14.28 |
| 2026-05-22 | RGNX | -0.42 | -0.49 | 14.28 |
| 2026-05-26 | RGNX | -0.42 | 3.47 | 14.28 |
| 2026-05-27 | RGNX | -0.42 | 3.47 | 14.28 |
| 2026-05-28 | RGNX | -0.42 | 3.47 | 15.22 |
| 2026-05-29 | RGNX | -0.42 | 3.47 | 15.22 |
| 2026-06-02 | RGNX | -0.42 | 2.77 | 15.22 |
| 2026-06-03 | RGNX | -0.42 | 2.77 | 15.22 |
| 2026-06-04 | RGNX | -0.42 | 2.77 | 15.22 |
| 2026-06-05 | RGNX | -0.42 | 2.77 | 15.22 |
| 2026-06-08 | RGNX | -0.42 | 2.77 | 15.27 |
| 2026-06-09 | RGNX | -0.41 | 2.77 | 15.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.72
Avg. EPS Est. Current Quarter
0.34
Avg. EPS Est. Next Quarter
-1.48
Insider Transactions
-0.41
Institutional Transactions
2.77
Beta
1.05
Average Sales Estimate Current Quarter
119
Average Sales Estimate Next Quarter
23
Fair Value
Quality Score
28
Growth Score
32
Sentiment Score
20
Actual DrawDown %
86.4
Max Drawdown 5-Year %
-88.4
Target Price
25.58
P/E
Forward P/E
PEG
P/S
3.73
P/B
15.52
P/Free Cash Flow
EPS
-5.59
Average EPS Est. Cur. Y
-2.85
EPS Next Y. (Est.)
-2.52
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-330.23
Relative Volume
1.31
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.8
EPS 1 30Days Diff
-0.85
EBIT Estimation
◆
RGNX
Healthcare
$6.34
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
40.5
Range 1M
14.3%
Sup Dist
6.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
23.2%
EPS NY
-4.6%
52W%
7.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+303.5% upside
Upside
+303.5%
Quality
28
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 371
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
RGNX
Latest News
—
Caricamento notizie per RGNX…
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading